Skip to main content
Top
Published in: Familial Cancer 3/2011

01-09-2011

A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families

Authors: Kathleen Y. Yang, Aaron B. Caughey, Sarah E. Little, Michael K. Cheung, Lee-May Chen

Published in: Familial Cancer | Issue 3/2011

Login to get access

Abstract

Women at risk for Lynch Syndrome/HNPCC have an increased lifetime risk of endometrial and ovarian cancer. This study investigates the cost-effectiveness of prophylactic surgery versus surveillance in women with Lynch Syndrome. A decision analytic model was designed incorporating key clinical decisions and existing probabilities, costs, and outcomes from the literature. Clinical forum where risk-reducing surgery and surveillance were considered. A theoretical population of women with Lynch Syndrome at age 30 was used for the analysis. A decision analytic model was designed comparing the health outcomes of prophylactic hysterectomy with bilateral salpingo-oophorectomy at age 30 versus annual gynecologic screening versus annual gynecologic exam. The literature was searched for probabilities of different health outcomes, results of screening modalities, and costs of cancer diagnosis and treatment. Cost-effectiveness expressed in dollars per discounted life-years. Risk-reducing surgery is the least expensive option, costing $23,422 per patient for 25.71 quality-adjusted life-years (QALYs). Annual screening costs $68,392 for 25.17 QALYs; and annual examination without screening costs $100,484 for 24.60 QALYs. Further, because risk-reducing surgery leads to both the lowest costs and the highest number of QALYs, it is a dominant strategy. Risk-reducing surgery is the most cost-effective option from a societal healthcare cost perspective.
Literature
1.
go back to reference Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214–218PubMedCrossRef Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214–218PubMedCrossRef
2.
go back to reference Dunlop MG, Farrington SM, Carothers AD et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105–110PubMedCrossRef Dunlop MG, Farrington SM, Carothers AD et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105–110PubMedCrossRef
3.
go back to reference Jarvinen HJ, Mecklin JP, Sistonen P (1995) Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108:1405–1411PubMedCrossRef Jarvinen HJ, Mecklin JP, Sistonen P (1995) Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108:1405–1411PubMedCrossRef
4.
go back to reference Vasen HF, van Ballegooijen M, Buskens E et al (1998) A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 82:1632–1637PubMedCrossRef Vasen HF, van Ballegooijen M, Buskens E et al (1998) A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 82:1632–1637PubMedCrossRef
5.
go back to reference Burke W, Petersen G, Lynch P et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 277:915–919PubMedCrossRef Burke W, Petersen G, Lynch P et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 277:915–919PubMedCrossRef
6.
go back to reference Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261–269PubMedCrossRef Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261–269PubMedCrossRef
7.
go back to reference Watson P, Butzow R, Lynch HT et al (2001) The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 82:223–228PubMedCrossRef Watson P, Butzow R, Lynch HT et al (2001) The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 82:223–228PubMedCrossRef
8.
go back to reference Chen LM, Yang KY, Little SE, Cheung MK, Caughey AB (2007) Gynecologic cancer prevention in lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol 110:18–25PubMedCrossRef Chen LM, Yang KY, Little SE, Cheung MK, Caughey AB (2007) Gynecologic cancer prevention in lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol 110:18–25PubMedCrossRef
9.
go back to reference Kwon J, Sun C, Peterson S et al (2008) Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch Syndrome. Cancer 113(2):326–335PubMedCrossRef Kwon J, Sun C, Peterson S et al (2008) Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch Syndrome. Cancer 113(2):326–335PubMedCrossRef
10.
go back to reference Lindor NM, Petersen GM, Hadley DW et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296:1507–1517PubMedCrossRef Lindor NM, Petersen GM, Hadley DW et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296:1507–1517PubMedCrossRef
11.
go back to reference Cowett AA, Golub RM, Grobman WA (2006) Cost-effectiveness of dilation and evacuation versus the induction of labor for second-trimester pregnancy termination. Am J Obstet Gynecol 194:768–773PubMedCrossRef Cowett AA, Golub RM, Grobman WA (2006) Cost-effectiveness of dilation and evacuation versus the induction of labor for second-trimester pregnancy termination. Am J Obstet Gynecol 194:768–773PubMedCrossRef
12.
go back to reference Baker M, Kessler L, Smucker R (1989) Site-specific treatment costs for cancer: an analysis of the medicare continuous history sample file. In: Society AC (ed) Cancer Care and Cost 127–138 Baker M, Kessler L, Smucker R (1989) Site-specific treatment costs for cancer: an analysis of the medicare continuous history sample file. In: Society AC (ed) Cancer Care and Cost 127–138
13.
go back to reference McGuire W, Neugut AI, Arikian S, Doyle J, Dezii CM (1997) Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 15:640–645PubMed McGuire W, Neugut AI, Arikian S, Doyle J, Dezii CM (1997) Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 15:640–645PubMed
14.
go back to reference Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615PubMedCrossRef Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615PubMedCrossRef
15.
go back to reference Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622PubMedCrossRef Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622PubMedCrossRef
16.
go back to reference Anderson K, Jacobson JS, Heitjan DF et al (2006) Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Int Med 144:397–406PubMed Anderson K, Jacobson JS, Heitjan DF et al (2006) Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Int Med 144:397–406PubMed
17.
go back to reference Kwon JS, Sun CC, Peterson SK, White KG et al (2008) Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch Syndrome. Cancer 113:326–335PubMedCrossRef Kwon JS, Sun CC, Peterson SK, White KG et al (2008) Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch Syndrome. Cancer 113:326–335PubMedCrossRef
18.
go back to reference Carter KJ, Ritchey NP, Castro F et al (1998) Treatment of early-stage breast cancer in the elderly: a health-outcome-based approach. Med Decis Mak 18:213–219 Carter KJ, Ritchey NP, Castro F et al (1998) Treatment of early-stage breast cancer in the elderly: a health-outcome-based approach. Med Decis Mak 18:213–219
19.
go back to reference Grann VR, Sundararajan V, Jacobson JS et al (2000) Decision analysis of tamoxifen for the prevention of invasive breast cancer. Cancer J 6:169–178PubMed Grann VR, Sundararajan V, Jacobson JS et al (2000) Decision analysis of tamoxifen for the prevention of invasive breast cancer. Cancer J 6:169–178PubMed
20.
go back to reference Hillner BE, Hollenberg JP, Pauker SG (1986) Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered. Am J Med 80:1115–1127PubMedCrossRef Hillner BE, Hollenberg JP, Pauker SG (1986) Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered. Am J Med 80:1115–1127PubMedCrossRef
21.
go back to reference Weinstein MC, Schiff I (1983) Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 38:445–455PubMedCrossRef Weinstein MC, Schiff I (1983) Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 38:445–455PubMedCrossRef
22.
go back to reference Sun CC (2006) Preferences for cancer prevention strategies (CPS) in women with hereditary nonpolyposis colorectal cancer (HNPCC). J Clin Oncol 24(18S June 20 suppl):1018. Abstract 1018 Sun CC (2006) Preferences for cancer prevention strategies (CPS) in women with hereditary nonpolyposis colorectal cancer (HNPCC). J Clin Oncol 24(18S June 20 suppl):1018. Abstract 1018
23.
go back to reference Grann VR, Jacobson JS, Thomason D et al (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20:2520–2529PubMedCrossRef Grann VR, Jacobson JS, Thomason D et al (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20:2520–2529PubMedCrossRef
24.
go back to reference Grann VR, Panageas KS, Whang W et al (1998) Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 16:979–985PubMed Grann VR, Panageas KS, Whang W et al (1998) Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 16:979–985PubMed
25.
go back to reference Ortega A, Dranitsaris G, Sturgeon J et al (1997) Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 66:454–463PubMedCrossRef Ortega A, Dranitsaris G, Sturgeon J et al (1997) Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 66:454–463PubMedCrossRef
26.
go back to reference Plevritis SK, Kurian AW, Sigal BM et al (2006) Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 295:2374–2384PubMedCrossRef Plevritis SK, Kurian AW, Sigal BM et al (2006) Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 295:2374–2384PubMedCrossRef
27.
go back to reference Van Roosmalen MS, Verhoef LC, Stalmeler PF et al (2002) Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oohorectomy. J Clin Oncol 20:2092–2100PubMedCrossRef Van Roosmalen MS, Verhoef LC, Stalmeler PF et al (2002) Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oohorectomy. J Clin Oncol 20:2092–2100PubMedCrossRef
28.
go back to reference Grindedal EM, Renkonen-Sinisalo L, Vasen H et al (2010) Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. J Med Genet 47:99–102PubMedCrossRef Grindedal EM, Renkonen-Sinisalo L, Vasen H et al (2010) Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. J Med Genet 47:99–102PubMedCrossRef
Metadata
Title
A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families
Authors
Kathleen Y. Yang
Aaron B. Caughey
Sarah E. Little
Michael K. Cheung
Lee-May Chen
Publication date
01-09-2011
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2011
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-011-9444-z

Other articles of this Issue 3/2011

Familial Cancer 3/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine